Our Company
Virex Pharma is developing proprietary nano-emulsion formulations of an anti-viral drug to treat respiratory and encephalitic viral infections.
The Active Pharmaceutical Ingredient (API) has been used as a treatment for Hepatitis B and C in Asia since 1977 having demonstrated good clinical safety and efficacy in the treatment of hepatitis. Previously delivered intravenously in hospital settings, Virex Pharma has reformulated as a nanoemulsion to deliver it directly into the site of infection in non-clinical settings for respiratory viral infections and as a nasal spray for encephalitic infections.
The antiviral drug has broad spectrum activity against Influenza A A/H3N2, H1N1, H5N1, Human Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Coronaviruses.
The Company is developing nanoemulsion formulations as broad-spectrum antiviral treatments for respiratory and encephalitic infections, initially focusing its development for its use as treatments of Respiratory Syncytial Virus (RSV), SARS-COV-2 Virus (COVID-19), and Dengue.
Respiratory Syncytial Virus (RSV)
COVID-19
The COVID-19 pandemic began in late 2019 with the virus evolving into a number of variants resulting in waves of infections around the globe. To date more than 6 million people worldwide are claimed to have lost their lives because of COVID-19 infection.
